By Dion Warren, Head, Oncology Business Unit, U.S., Takeda Oncology and Rachael Brake, PhD, Head, Medical Affairs, U.S., Takeda Oncology
Unlocking the most promising science
Each spring the oncology community convenes to share and exchange scientific advancements and gain insights from both physician and patient voices which have the potential to change the course of cancer care. We look forward to such conversations and anticipate a few trends at upcoming medical congresses: improving patient care, advances in immuno-oncology and partnerships to drive research forward.
Takeda Oncology will participate in this year’s virtual ASCO, EHA and BIO — where we will present our latest advancements, as well as demonstrate our commitment to the development of transformative treatments for underserved patients with serious illnesses. We are equally looking forward to sharing our scientific progress with our ongoing partners and forging new ones to unlock the most promising science, wherever it emerges.
Patient-driven innovation in lung and hematologic cancers
We are committed to outsmarting cancer so more patients can benefit from — and have access to — life-transforming medicines for lung and hematologic cancers.
Key data from Takeda Oncology’s portfolio and pipeline to be presented at ASCO will highlight progress in targeted treatment options to address patients’ tumors that demonstrate mutations in EGFR Exon20 metastatic non-small cell lung cancer (mNSCLC), as well as optimization of chronic-phase chronic myeloid leukemia (CP-CML) treatment to maximize care, particularly in those with resistant or intolerant disease. We’re also looking forward to presenting additional updates from our hematology portfolio and pipeline at EHA.
We expect to see continued advances in immuno-oncology at ASCO, and we plan to further contribute to the future of cancer research in this area by sharing trial-in-progress posters at the congress from two investigative therapies that harness the power of innate immunity: a first-in-class SUMOylation inhibitor being studied in multiple cancers and a novel STING agonist being studied in solid tumors.
As we look ahead, we anticipate collaboration within the oncology community to continue to be a key driver of industry progress, and to remain a key priority for Takeda. At BIO, we look forward to discussing with key partners our goal to deliver cutting-edge treatments to patients faster through collaboration. Partnering with the brightest minds across academia, biotechnology and pharmaceuticals to share knowledge helps us identify and uncover the best methods to attack cancer.
Innovative partnership models can make it possible to bring novel approaches in immuno-oncology to patients with hematologic and solid tumors. For example:
- We recently acquired Maverick Therapeutics, a company we entered into a “build-to-buy” partnership with several years ago to develop a first-in-class conditionally active bispecific T-cell targeted immunotherapy in solid tumors.
- Additionally, it is through our partnership with Turnstone Biologics that we are jointly developing a novel form of oncolytic immunotherapy that utilizes viruses, specifically the vaccinia virus in our collaboration, to infect and destroy cancer cells.
We are grateful for and proud of these symbiotic partnerships as they help us reach innovative science to support our mission to impact patients’ lives.
Inspiration from patients. Innovation from everywhere.
We’re excited to virtually connect with the scientific community this spring to discuss data and innovative ideas for improving patient outcomes — particularly those who have limited or ineffective treatment options.
Our continued investigation of our pipeline and portfolio products is fueled by our dedication to translating science into potentially curative or transformative treatments. We must continue to be catalysts for scientific innovation because cancer finds new ways to prevail and patients desperately need new options. Cancer is clever, but we know its weaknesses.